Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential (Q40389389)

20 September 2017

1 reference

title

Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential (English)

1 reference

20 September 2017

1 reference

2

R N Brogden

1 reference

20 September 2017

H M Bryson

1

1 reference

20 September 2017

1 March 1994

1 reference

20 September 2017

1 reference

20 September 2017

47

1 reference

20 September 2017

506-535

1 reference

20 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199447030-00008

20 September 2017

0 references

cites work

Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics

1 reference

12 December 2020

Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents

1 reference

12 December 2020

Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

1 reference

12 December 2020

Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.

1 reference

12 December 2020

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

1 reference

12 December 2020

Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.

1 reference

12 December 2020

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

1 reference

12 December 2020

Effect of pH on antibiotics used to treat anaerobic infection

1 reference

12 December 2020

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

1 reference

12 December 2020

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.

1 reference

12 December 2020

Desethyl piperacillin, a new active metabolite of piperacillin in human

1 reference

12 December 2020

Tazobactam prevention of emergence of resistance.

1 reference

12 December 2020

Piperacillin kinetics

1 reference

12 December 2020

The effect of tazobactam on bilirubin-albumin binding

1 reference

12 December 2020

Determinants of the activity of beta-lactamase inhibitor combinations

1 reference

12 December 2020

Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography

1 reference

12 December 2020

In vitro susceptibilities of Plesiomonas shigelloides to 24 antibiotics and antibiotic-beta-lactamase-inhibitor combinations

1 reference

12 December 2020

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections

1 reference

12 December 2020

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

1 reference

12 December 2020

Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

1 reference

12 December 2020

Piperacillin/tazobactam in the treatment of serious acute soft tissue infection

1 reference

12 December 2020

Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests

1 reference

12 December 2020

Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria

1 reference

12 December 2020

Meeting the challenges of beta-lactamases

1 reference

12 December 2020

Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations

1 reference

12 December 2020

Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

12 December 2020

Therapy of soft tissue infections with piperacillin/tazobactam

1 reference

12 December 2020

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria

1 reference

12 December 2020

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections

1 reference

12 December 2020

The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam

1 reference

12 December 2020

In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis

1 reference

12 December 2020

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam

1 reference

12 December 2020

Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

1 reference

12 December 2020

Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group

1 reference

12 December 2020

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

1 reference

12 December 2020

In vitro synergistic activity of piperacillin-tazobactam combination against beta-lactam antibiotics resistant strains of Enterobacteriaceae

1 reference

12 December 2020

Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Piperacillin/tazobactam in complicated urinary tract infections.

1 reference

12 December 2020

In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.

1 reference

12 December 2020

In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria

1 reference

12 December 2020

Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria

1 reference

12 December 2020

Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.

1 reference

12 December 2020

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

1 reference

12 December 2020

Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease

1 reference

12 December 2020

Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

1 reference

12 December 2020

Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid

1 reference

12 December 2020

Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins.

1 reference

12 December 2020

Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam

1 reference

12 December 2020

In vitro susceptibilities of Edwardsiella tarda to 22 antibiotics and antibiotic-beta-lactamase-inhibitor agents.

1 reference

12 December 2020

Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636.

1 reference

12 December 2020

Diverse potential of beta-lactamase inhibitors to induce class I enzymes

1 reference

12 December 2020

Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy

1 reference

12 December 2020

Penicillins. A current review of their clinical pharmacology and therapeutic use.

1 reference

12 December 2020

Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria

1 reference

12 December 2020

Treatment of intra-abdominal infections

1 reference

12 December 2020

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

1 reference

12 December 2020

Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.

1 reference

12 December 2020

Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors

1 reference

12 December 2020

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

1 reference

12 December 2020

Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant

1 reference

12 December 2020

Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae

1 reference

12 December 2020

Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli

1 reference

12 December 2020

Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance

1 reference

12 December 2020

Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.

1 reference

12 December 2020

Intraabdominal infections: an overview.

1 reference

12 December 2020

Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli

1 reference

12 December 2020

Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies

1 reference

12 December 2020

Effect of piperacillin/tazobactam therapy on intestinal microflora

1 reference

12 December 2020

Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group

1 reference

12 December 2020

Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli

1 reference

12 December 2020

Pseudomonas pseudomallei, a common pathogen in Thailand that is resistant to the bactericidal effects of many antibiotics

1 reference

12 December 2020

Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.

1 reference

12 December 2020

Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes

1 reference

12 December 2020

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

12 December 2020

Safety profile of piperacillin/tazobactam in phase I and III clinical studies

1 reference

12 December 2020

In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

1 reference

12 December 2020

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin

1 reference

12 December 2020

A proposed classification of intra-abdominal infections. Stratification of etiology and risk for future therapeutic trials

1 reference

12 December 2020

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group

1 reference

12 December 2020

In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents

1 reference

12 December 2020

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

1 reference

12 December 2020

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

1 reference

12 December 2020

In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.

1 reference

12 December 2020

Beta-lactamase inhibitors from laboratory to clinic

1 reference

12 December 2020

Should quinolones be used in the treatment of bacterial infections in neutropenic patients?

1 reference

12 December 2020

Susceptibility of cefoxitin-resistant isolates of bacteroides to other agents including beta-lactamase inhibitor/beta-lactam combinations

1 reference

12 December 2020

Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam

1 reference

12 December 2020

Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations

1 reference

12 December 2020

In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam

1 reference

12 December 2020

Purification and characterization of an imipenem hydrolysing metallo-beta-lactamase from Bacteroides fragilis

1 reference

12 December 2020

β-Lactamase inhibitors in perspective

1 reference

12 December 2020

Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles

1 reference

12 December 2020

Increased in vitro activity of ceftriaxone by addition of tazobactam against clinical isolates of anaerobes

1 reference

12 December 2020

In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor

1 reference

12 December 2020

Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin

1 reference

12 December 2020

Activity of the beta-lactamase inhibitor BRL 42715 against cephalosporinases produced by Enterobacteriaceae.

1 reference

12 December 2020

In-vitro activity of four penicillin/beta-lactamase inhibitor combinations against cefoxitin-susceptible and cefoxitin-resistant Bacteroides fragilis isolates.

1 reference

12 December 2020

Susceptibility of Escherichia coli isolates with TEM-1 β-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin

1 reference

12 December 2020

Poor induction of beta-lactamases by tazobactam

1 reference

12 December 2020

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

1 reference

12 December 2020

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

1 reference

12 December 2020

Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria

1 reference

12 December 2020

In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus.

1 reference

12 December 2020

Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.

1 reference

12 December 2020

Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam

1 reference

12 December 2020

10.2165/00003495-199447030-00008

Identifiers

DOI

1 reference

PubMed ID

7514977

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

7514977